ASMB:NSD-Assembly Biosciences, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.06

Change

0.00 (0.00)%

Market Cap

USD 0.16B

Volume

1.23M

Average Target Price

USD 10.00 (+146.31%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H2158, which is in Phase II clinical study for chronic HBV infection; ABI-H3733 that has completed Phase Ia clinical study for the treatment of HBV. The company has collaboration agreements with Allergan Pharmaceuticals International Limited; BeiGene, Ltd.; and Arbutus Biopharma Corporation, as well as strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

USD79.98B 133.51 104.16
REGN Regeneron Pharmaceuticals, Inc

N/A

USD57.31B 15.31 11.96
BNTX BioNTech SE

N/A

USD51.30B -99,999.99 31.95
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD48.63B 17.91 12.34
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.06B 58.65 41.96
BGNE BeiGene, Ltd

N/A

USD29.61B N/A N/A
SGEN Seagen Inc

N/A

USD28.37B 43.61 39.21
GMAB Genmab A/S

N/A

USD28.05B 26.59 3.73
RPRX Royalty Pharma plc

N/A

USD26.73B 22.60 15.75
ALNY Alnylam Pharmaceuticals, Inc

N/A

USD20.79B N/A N/A

ETFs Containing ASMB

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -32.89% 14% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.89% 14% F 7% F
Trailing 12 Months  
Capital Gain -81.88% 1% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -81.88% 1% F 1% F
Trailing 5 Years  
Capital Gain -30.00% 39% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.00% 39% F 15% F
Average Annual (5 Year Horizon)  
Capital Gain 31.86% 64% D 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.86% 64% D 77% C+
Risk Return Profile  
Volatility (Standard Deviation) 113.86% 23% F 13% F
Risk Adjusted Return 27.98% 53% F 46% F
Market Capitalization 0.16B 29% F 28% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.68 99% A+ 97% A+
Price / Cash Flow Ratio -2.59 18% F 62% D-
EV/EBITDA 0.61 53% F 92% A-
Management Effectiveness  
Return on Equity -25.13% 80% B- 32% F
Return on Invested Capital -25.21% 75% C 26% F
Return on Assets -12.52% 79% C+ 25% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.07 44% F 25% F
Short Percent 13.95% 16% F 12% F
Beta 0.33 89% B+ 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector